{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:03:07Z","timestamp":1782907387200,"version":"3.54.5"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontierspartnerships.org"],"crossmark-restriction":true},"short-container-title":["Transpl Int"],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Donor hepatitis-C (HCV) infection has historically represented a barrier to kidney transplantation (KT). However, direct-acting antiviral (DAA) medications have revolutionised treatment of chronic HCV infection. Recent American studies have demonstrated that DAA regimes can be used safely peri-operatively in KT to mitigate HCV transmission risk.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> To formulate this narrative review, a comprehensive literature search was performed to analyse results of existing clinical trials examining KT from HCV-positive donors to HCV-negative recipients with peri-operative DAA regimes.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> 13 studies were reviewed (11 single centre, four retrospective). Outcomes for 315 recipients were available across these studies. A sustained virological response at 12\u00a0weeks (SVR12) of 100% was achieved in 11 studies. One study employed an ultra-short DAA regime and achieved an SVR12 of 98%, while another achieved SVR12 of 96% due to treatment of a missed mixed genotype.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> HCV+ KT is safe and may allow increased utilisation of organs for transplantation from HCV+ donors, who often have other favourable characteristics for successful donation. Findings from US clinical trials can be applied to the United Kingdom transplant framework to improve organ utilisation as suggested by the NHSBT vision strategy <jats:italic>\u201cOrgan Donation and Transplantation 2030: meeting the need\u201d.<\/jats:italic><\/jats:p>","DOI":"10.3389\/ti.2022.10277","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T04:11:23Z","timestamp":1651551083000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Kidney Transplantation From Hepatitis-C Viraemic Donors:Considerations for Practice in the United Kingdom"],"prefix":"10.3389","volume":"35","author":[{"given":"Daniel T.","family":"Doherty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varinder","family":"Athwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zia","family":"Moinuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titus","family":"Augustine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"van Dellen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein A.","family":"Khambalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJM199108153250702","article-title":"Transmission of Hepatitis C Virus by Organ Transplantation","volume":"325","author":"Pereira","year":"1991","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1097\/00007890-199504150-00030","article-title":"Interferon - \u03b1 - Induced Acute Renal Allograft Rejection","volume":"59","author":"Magnone","year":"1995","journal-title":"Transplantation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1111\/ajt.14381","article-title":"The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation","volume":"17","author":"Levitsky","year":"2017","journal-title":"Am J Transplant"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1111\/ajt.13776","article-title":"Increases in Drug and Opioid Overdose Deaths - United States, 2000-2014","volume":"16","author":"Rudd","year":"2016","journal-title":"Am J Transpl"},{"key":"B6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1155\/2007\/796325","article-title":"Factors Associated with Spontaneous Clearance of Hepatitis C Virus Among Illicit Drug Users","volume":"21","author":"Grebely","year":"2007","journal-title":"Can J Gastroenterol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1097\/TP.0000000000001410","article-title":"Use of HCV+ Donors Does Not Affect HCV Clearance with Directly Acting Antiviral Therapy but Shortens the Wait Time to Kidney Transplantation","volume":"101","author":"Sawinski","year":"2017","journal-title":"Transplantation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/tri.12954","article-title":"Transplantation of Kidneys from Hepatitis C-Positive Donors into Hepatitis C Virus-Infected Recipients Followed by Early Initiation of Direct Acting Antiviral Therapy: a Single-center Retrospective Study","volume":"30","author":"Bhamidimarri","year":"2017","journal-title":"Transpl Int"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/nejmc1705221","article-title":"Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients","volume":"376","author":"Goldberg","year":"2017","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"523","DOI":"10.7326\/M17-2871","article-title":"Direct-acting Antiviral Prophylaxis in Kidney Transplantation from Hepatitis C Virus-Infected Donors to Noninfected Recipients an Open-Label Nonrandomized Trial","volume":"168","author":"Durand","year":"2018","journal-title":"Ann Intern Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.kint.2021.06.034","article-title":"A Review of Kidney Transplantation from HCV-Viremic Donors into HCV-Negative Recipients","volume":"100","author":"Daloul","year":"2021","journal-title":"Kidney Int"},{"key":"B12","doi-asserted-by":"publisher","first-page":"50686","DOI":"10.1681\/ASN.2020050686","article-title":"Multicenter Study to Transplant Hepatitis C\u2013Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection","volume":"11","author":"Sise","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ekir.2020.01.001","article-title":"Preemptive Treatment with Elbasvir and Grazoprevir for Hepatitis C-Viremic Donor to Uninfected Recipient Kidney Transplantation","volume":"5","author":"Sise","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.7326\/M20-1468","article-title":"Four-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation from Hepatitis C\u2013Viremic Donors to Hepatitis C\u2013Negative Recipients: An Open-Label Nonrandomized Study","volume":"174","author":"Durand","year":"2020","journal-title":"Ann Intern Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm10010089","article-title":"Pan-Genotype Pre-exposure Prophylaxis (PrEP) Allows Transplantation of HCV-Positive Donor Kidneys to Negative Transplant Recipients","volume":"10","author":"Duerr","year":"2021","journal-title":"J Clin Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e13540","DOI":"10.1111\/tid.13540","article-title":"Hepatitis C-Positive Donor to Negative Recipient Kidney Transplantation: A Real-World Experience","volume":"23","author":"Jandovitz","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/ajt.15664","article-title":"Ultra-short Duration Direct Acting Antiviral Prophylaxis to Prevent Virus Transmission from Hepatitis C Viremic Donors to Hepatitis C Negative Kidney Transplant Recipients","volume":"20","author":"Gupta","year":"2020","journal-title":"Am J Transpl"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1056\/nejmoa1812406","article-title":"Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients","volume":"380","author":"Woolley","year":"2019","journal-title":"N Engl J Med"},{"key":"B19","first-page":"102","article-title":"Toxicity and Risks from Drug-To-Drug Interactions of New Antivirals for Chronic Hepatitis C","volume":"21","author":"Binda","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/s2468-1253(20)30081-9","article-title":"Short-course, Direct-Acting Antivirals and Ezetimibe to Prevent HCV Infection in Recipients of Organs from HCV-Infected Donors: a Phase 3, single-centre, Open-Label Study","volume":"5","author":"Feld","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B21","volume-title":"Ciclosporin | Interactions","year":"2021"},{"key":"B22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/nm.2581","article-title":"Identification of the Niemann-Pick C1-like 1 Cholesterol Absorption Receptor as a New Hepatitis C Virus Entry Factor","volume":"18","author":"Sainz","year":"2012","journal-title":"Nat Med"},{"key":"B23","doi-asserted-by":"crossref","first-page":"e13055","DOI":"10.1111\/tid.13055","article-title":"Infections and Associated Behaviors Among Deceased Organ Donors: Informing the Assessment of Risk","volume":"21","author":"Davison","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"B24","volume-title":"Safe Supplies: Data in Context. Annual Review from the NHS Blood and Transplant\/Public Health England Epidemiology Unit","year":"2019"},{"key":"B25","volume-title":"Safe Supplies: Monitor, inform, progress. Annual Review from the NHS Blood and Transplant\/Public Health England Epidemiology Unit","year":"2018"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1111\/ajt.15031","article-title":"Transplantation of Hepatitis C Virus (HCV) Antibody Positive, Nucleic Acid Test Negative Donor Kidneys to HCV Negative Patients Frequently Results in Seroconversion but Not HCV Viremia","volume":"18","author":"de Vera","year":"2018","journal-title":"Am J Transpl"},{"key":"B27","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/j.1432-2277.2009.01025.x","article-title":"No Evidence of Occult Hepatitis C Virus (HCV) Infection in Serum of HCV Antibody-Positive HCV RNA-Negative Kidney-Transplant Patients","volume":"23","author":"Nicot","year":"2009","journal-title":"Transpl Int"},{"key":"B28","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/tri.13410","article-title":"Renal Transplantation from Seropositive Hepatitis C Virus Donors to Seronegative Recipients in Spain: a Prospective Study","volume":"32","author":"Franco","year":"2019","journal-title":"Transpl Int"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e13146","DOI":"10.1111\/tid.13146","article-title":"Successful Early Sofosbuvir-Based Antiviral Treatment after Transplantation of Kidneys from HCV-Viremic Donors into HCV-Negative Recipients","volume":"21","author":"Friebus-Kardash","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"B30","volume-title":"Meeting the Need 2030 - ODT Clinical - NHS Blood and Transplant. London, NHSBT","year":"2021"},{"key":"B31","volume-title":"Annual Activity Report - ODT Clinical - NHS Blood and Transplant. London, NHSBT","year":"2021"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1111\/ajt.15530","article-title":"Transplantation of Kidneys from Hepatitis C\u2013Infected Donors to Hepatitis C\u2013Negative Recipients: Single center Experience","volume":"19","author":"Molnar","year":"2019","journal-title":"Am J Transpl"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1111\/ajt.15582","article-title":"Lessons from the Real World: HCV-Infected Donor Kidney Transplantation as Standard Practice","volume":"19","author":"Durand","year":"2019","journal-title":"Am J Transplant"},{"key":"B34","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.31011","article-title":"Hepatitis C Virus NAT-Positive Solid Organ Allografts Transplanted into Hepatitis C Virus\u2013Negative Recipients: A Real-World Experience","volume":"72","author":"Kapila","year":"2020","journal-title":"Hepatology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/ajt.15583","article-title":"Fibrosing Cholestatic Hepatitis after Kidney Transplantation from <scp>HCV<\/scp> \u2010viremic Donors to <scp>HCV<\/scp> \u2010negative Recipients: A Unique Complication in the <scp>DAA<\/scp> Era","volume":"20","author":"Kapila","year":"2020","journal-title":"Am J Transpl"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1681\/asn.2020050686","article-title":"Multicenter Study to Transplant Hepatitis C-Infected Kidneys (Mythic): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection","volume":"31","author":"Sise","year":"2020","journal-title":"Jasn"},{"key":"B37","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/ajt.16834","article-title":"Association of Donor Hepatitis C Virus Infection Status and Risk of BK Polyomavirus Viremia after Kidney Transplantation","volume":"22","author":"Molnar","year":"2022","journal-title":"Am J Transpl"},{"key":"B38","volume-title":"Recommendations: Glecaprevir-Pibrentasvir for Treating Chronic Hepatitis C. London, NICE","year":"2017"},{"key":"B39","volume-title":"Chronic Kidney Disease in England: The Human and Financial Cost","year":"2012"},{"key":"B40","volume-title":"UK Position Statement on the Use of Organs from Hepatitis C Viraemic Donors and Increased Infectious Risk Donors in Hepatitis C Negative Recipients 2","year":"2021"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1111\/ajt.14929","article-title":"Cost-effectiveness of Using Kidneys from Hepatitis C Nucleic Acid Test-Positive Donors for Transplantation in Hepatitis C-Negative Recipients","volume":"18","author":"Kadatz","year":"2018","journal-title":"Am J Transpl"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e13684","DOI":"10.1111\/tid.13684","article-title":"Lung Transplant Recipient Attitudes and Beliefs on Accepting an Organ that Is Positive for Hepatitis C Virus","volume":"23","author":"Humar","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"B43","doi-asserted-by":"crossref","first-page":"e13402","DOI":"10.1111\/tid.13402","article-title":"Post-transplant Survey to Assess Patient Experiences with Donor-Derived HCV Infection","volume":"22","author":"Prakash","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1080\/23294515.2019.1670277","article-title":"Patient\u2019s Perspectives of Experimental HCV-Positive to HCV-Negative Renal Transplantation","volume":"11","author":"Rasmussen","year":"2020","journal-title":"AJOB Empir Bioeth"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/S0140-6736(09)61116-8","article-title":"No Surgical Innovation without Evaluation: the IDEAL Recommendations","volume":"374","author":"McCulloch","year":"2009","journal-title":"The Lancet"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1002\/hep.31551","article-title":"Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors","volume":"73","author":"Terrault","year":"2021","journal-title":"Hepatology"}],"container-title":["Transplant International"],"original-title":[],"link":[{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2022.10277\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T04:11:32Z","timestamp":1651551092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2022.10277\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":46,"alternative-id":["10.3389\/ti.2022.10277"],"URL":"https:\/\/doi.org\/10.3389\/ti.2022.10277","relation":{},"ISSN":["1432-2277"],"issn-type":[{"value":"1432-2277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,3]]},"article-number":"10277"}}